Chandrasekhar Bal

18PUBLICATIONS

3CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyMolecular targetsPredictive and prognostic markersChild and adolescent development

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (18)

Sort by Publication Date:

|Jun 25, 2026

Long-term outcomes in medullary thyroid cancer patients treated with [177Lu]Lu-DOTAGA.FAPi dimer therapy.

|Feb 04, 2025

Low-Dose Versus High-Dose Lenvatinib in Radioiodine Refractory Differentiated Thyroid Cancer-A Real-World Safety and Efficacy Analysis.

Jeepalem Sai Moulika, Kunal Ramesh Chandekar, Shubha Gadde Ravindra

|Mar 12, 2024

[177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study.

Swayamjeet Satapathy, Madhav Prasad Yadav, Sanjana Ballal

|Jan 12, 2024

Optimal Cumulative I-131 Activity in Metastatic Differentiated Thyroid Cancer: Balancing Efficacy and Adverse Events.

Mangu Srinivas Bharadwaj, Sanjana Ballal, Chandrasekhar Bal

|Dec 05, 2023

Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis.

Kunal Ramesh Chandekar, Swayamjeet Satapathy, Chandrasekhar Bal

|Nov 06, 2023

Therapeutic potential of [177Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment.

Madhav P Yadav, Sanjana Ballal, Marcel Martin

Pageof 3

Frequent Collaborators

2 joint publications

Swayamjeet Satapathy

1 joint publications

Alpesh Goyal

1 joint publications

Viveka P Jyotsna

Frequent Collaborators

2 joint publications

Swayamjeet Satapathy

1 joint publications

Alpesh Goyal

1 joint publications

Viveka P Jyotsna